← Browse by Condition
Medical Condition

dyslipidemias

Total Trials
5
Recruiting Now
5
Trial Phases
Phase 2, Phase 4

ClinicalMetric tracks all active clinical trials for dyslipidemias sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — dyslipidemias Clinical Trials

How many clinical trials are currently recruiting for dyslipidemias?
ClinicalMetric currently tracks 5 actively recruiting clinical trials for dyslipidemias, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 5. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for dyslipidemias?
dyslipidemias research spans Phase 2 (1 trial), Phase 4 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a dyslipidemias clinical trial?
Eligibility criteria for dyslipidemias trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Phase 4
1
Top Sponsors
Ribocure Pharmaceuticals AB 1 trial
Yonsei University 1 trial
Hospital Universitario La Paz 1 trial
Medical University of Bialystok 1 trial
JW Pharmaceutical 1 trial

Recruiting Clinical Trials

NCT06797401 Phase 2
Recruiting
Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia
Enrollment
120 pts
Location
Sweden
Sponsor
Ribocure Pharmaceuticals AB
View Trial →
NCT05705804
Recruiting
Effects of Pitavastatin or Combination of Pitavastatin and Ezetimibe on Glucose Metabolism Compared to AtoRvastatin in atheroscLerotic Cardiovascular Disease Patients With Metabolic Syndrome: The EZ-PEARL Randomized Trial
Enrollment
250 pts
Location
South Korea
Sponsor
Yonsei University
View Trial →
NCT06463561 Phase 4
Recruiting
CPAP Effect on Lipid Profile and Hyperuricemia in Patients With Dyslipidemia and Moderate-severe Obstructive Sleep Apnea
Enrollment
220 pts
Location
Spain
Sponsor
Hospital Universitario La Paz
View Trial →
NCT04634591
Recruiting
The Bialystok Bariatric Surgery Study
Enrollment
1,000 pts
Location
Poland
Sponsor
Medical University of Bialysto...
View Trial →
NCT07523971
Recruiting
Efficacy and Safety of Pitavastatin/Ezetimibe in Dyslipidemia Patients With Metabolic Syndrome: An Observational Study
Enrollment
10,000 pts
Location
South Korea
Sponsor
JW Pharmaceutical
View Trial →

Related Conditions

atherosclerotic cardiovascular disease (1) sleep apnea (1) hyperuricemia (1) obesity (1) diabetes mellitus (1) metabolic syndrome (1) prediabetes (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology